If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Nice one, thought it'll be a good day from Friday's positive end. Keep going up from it now
"Over 60 percent of COVID-19 positive patients had gastrointestinal symptoms, such as diarrhoea, nausea and vomiting, and the SARS-COV-2 virus was found in their faecal samples. Sampling waste water from households may therefore provide an early warning system for localised outbreaks in communities.".
So does that mean we will be able to make a judgement about how many in the infected population are asymptomatic then? - That might help a lot if so.
Shows the ability of Avacta to identify opportunities and negotiate deal. SKIN was mentioned last week so hats off to that insight (I didn't say that)
A great start to the week with a new application of the use of Affimers. We were told that they were working on new tests and partnerships and we now have another iron in the fire. I have a feeling this is going to be a very good week with further news expected on:
BAMS
LFD
Partnerships with large pharmaceutical regarding Affimer blocking treatment for Covid
Manufacturing partnerships
So much going on, who knows whats next. This could be your last chance to get in at this price.
GLA
£2B market by 2030
Key words from AS:
Substantial commercial potential
If these tests are going to happen at all it’s gonna be this week or next. Otherwise we get in the wtf is going on territory.
Multiple rns coming this week
Big al said so
This is the week
Testing to be completed over the next few weeks (again)........aye righto then.
Didn’t see that one coming!
;~)
GLA
That’s not too ****ty
This rns opens up multiple avenues
What a company we are involved in here
So exciting
RAWTest Opportunities:
· With 20 species of Listeria bacterium, every public building including hospitals, hotels, conference halls and senior citizen nursing homes are at risk of contamination
· Remote detection and analysis of malaria in blood in third world-countries and for military use
· In-line milking machines could detect mastitis in a single cow, enabling instant action to eliminate contamination with a dairy herd milk collection
· Early warning system in fermentation processes for ethanol, alcohol and wine producers at risk of bacterial hazard to improve consumer safety, shelf-life stability and longevity
1) why do RNSs not show up on this site anymore?
2). This would be a great RNS 3 months ago . Good PR but no real sales channel . Updates on the test please .
Going to be ?
He is going to be intolerable
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Collaboration with Integumen plc for Detection of SARS-COV-2 Coronavirus in Waste Water
Partnership to evaluate the use of Affimer reagents to detect the coronavirus using novel sensors
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Integumen plc (AIM: SKIN) ("Integumen") to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of the coronavirus in waste water, to provide a real-time alert system to warn of localised COVID-19 outbreaks.
Over 60 percent of COVID-19 positive patients had gastrointestinal symptoms, such as diarrhoea, nausea and vomiting, and the SARS-COV-2 virus was found in their faecal samples. Sampling waste water from households may therefore provide an early warning system for localised outbreaks in communities.
Recently, Avacta announced that it had generated a number of highly specific Affimer reagents that detect the SARS-COV-2 virus spike protein for use in diagnostic tests and in neutralising therapies.
The collaboration with Integumen announced today aims to evaluate some of these Affimer reagents in next-generation sensors, based on the real-time bacteria detection and alert system1 developed by Rinocloud Ltd, a subsidiary of Integumen, with the aim of integrating these sensors into Modern Water plc's Microtox water contamination system to detect the coronavirus. The award-winning Microtox system, which can detect the presence of contaminating bacteria, virus and toxins, is distributed by Modern Water and has a global footprint of over 3,000 installations. The proposed Affimer sensors would be consumable items to be replaced on a roughly monthly basis.
Once initial testing of the Affimer reagents is completed over the next few weeks, validation of the sensors will be carried out using SARS-COV-2 virus samples in a containment level 3 laboratory at the University of Aberdeen. Upon successful completion of this evaluation, Integumen and Avacta will enter into a supply agreement to allow Integumen to manufacture and commercialise the waste water detection sensors globally by retrofitting into Microtox systems.
Dr. Alastair Smith, Chief Executive of Avacta Group, commented:
"I am very pleased to be entering into this collaboration with Integumen, which holds substantial commercial potential for an Affimer-based consumable SARS-COV-2 detector unit to retrofit into the globally-installed base of Microtox systems. Affimer reagents are ideal for applications such as this, not only because of their sensitivity and specificity, but also because of their robustness, which is essential when being deployed in real-world situations, such as real-time waste water analysis.